Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson’s disease patients | Zendy

Yeşim Sücüllü Karadağ | Zendy; Tuğçe SALTOĞLU | Zendy; Fadime ERDOĞAN KÜÇÜKDAĞLI | Zendy; Ömer Öztürk | Zendy; Tankut KÖSEOĞLU | Zendy; Emin Altıparmak | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson’s disease patients

Author(s) -

Yeşim Sücüllü Karadağ,

Tuğçe SALTOĞLU,

Fadime ERDOĞAN KÜÇÜKDAĞLI,

Ömer Öztürk,

Tankut KÖSEOĞLU,

Emin Altıparmak

Publication year - 2020

Publication title -

turkish journal of medical sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.277

H-Index - 27

eISSN - 1303-6165

pISSN - 1300-0144

DOI - 10.3906/sag-2005-96

Subject(s) - medicine , turkish , levodopa , carbidopa , disease , parkinson's disease , gastroenterology , philosophy , linguistics

Levodopa-carbidopa intestinal gel (LCIG) is an effective treatment modality in the management of advanced Parkinson’s disease (PD) despite frequent adverse events and different rates of dropouts. Efficacy and safety data regarding Turkish patients on LCIG are limited. This study aims to report in detail the efficacy and adverse effect profile of LCIG among advanced PD patients from a Turkish center for movement disorders.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research